1,603 results on '"Ljungman, Per"'
Search Results
202. COVID-19 and Stem Cell Transplantation; Results from the Prospective Survey By the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)
203. 162 - Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplant Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation (EBMT), American Society for Transplantation and Cellular Therapy (ASTCT), Asia-Pacific Blood and Marrow Transplantation Group (APBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR)
204. A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors
205. Prophylaxis against Herpesvirus Infections in Transplant Recipients
206. Human herpesvirus-6 infection in solid organ and stem cell transplant recipients
207. Would monitoring CMV immune responses allow improved control of CMV in stem cell transplant patients
208. Viral Infections in Hematopoietic Stem Cell Transplant Recipients
209. Definitions of cytomegalovirus infection and disease in transplant recipients. (Immunocompromised Hosts)
210. Pharmacoeconomic Considerations in Treating Patients With Acute Leukaemia
211. Contributors
212. Vaccination in the immunocompromised host
213. The socioeconomic and psychosocial circumstances of adult long-term survivors of hematopoietic stem cell transplantation in childhood
214. Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults
215. Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT
216. A prospective study on the long‐term outcome of prepubertal and pubertal boys undergoing testicular biopsy for fertility preservation prior to hematologic stem cell transplantation
217. Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: A phase II study
218. Prognostic impact of Epstein-Barr virus serostatus in patients with nonmalignant hematological disorders undergoing allogeneic hematopoietic cell transplantation: the study of Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation
219. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation
220. Is antiviral therapy against HHV-6B beneficial?
221. Treosulfan conditioning for allogeneic transplantation in multiple myeloma – improved overall survival in first line haematopoietic stem cell transplantation – a large retrospective study by the Chronic Malignancies Working Party of the EBMT
222. Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study
223. Humoral immunity to tetanus, diphtheria and polio in adults after treatment for hematological malignancies
224. Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination
225. Should irradiated blood products be given routinely to all patients with aplastic anaemia undergoing immunosuppressive therapy with antithymocyte globulin (ATG)? A survey from the European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party
226. A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients
227. A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract
228. IL-7 Expression and Responsiveness in EBV Infection and EBV-Associated PTLD in Allogeneic HSCT Patients: P5
229. Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up
230. Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
231. Bone and hormonal status 10 years post‐allogeneic bone marrow transplantation
232. Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT
233. Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
234. Treosulfan Conditioning for Allogeneic Transplantation in Multiple Myeloma – Improved Overall Survival in first line Hematopoietic Stem Cell Transplantation
235. ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients
236. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA
237. Relapse of preB-ALL after rituximab treatment for chronic graft versus host disease. Implications for its use?
238. Allogeneic transplantation and treatment with donor lymphocytes
239. A prospective study of diagnosis of Toxoplasma gondii infection after bone marrow transplantation
240. Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
241. Incidence and outcome of kaposi sarcoma after hsct: A retrospective analysis on behalf of IDWP
242. MOESM1 of The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016
243. Immunisation of Transplant Recipients
244. Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influence of graft versus host reaction
245. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study
246. The value of CMV and fungal PCR for monitoring of acute leukaemia and autologous stem cell transplant patients
247. Allogenic stem cell transplantation for nonmalignant disorders using matched unrelated donors
248. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia
249. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?
250. Supportive treatment of patients with severe aplastic anemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.